EUCTR2007-001014-17-IT进行中（未招募）不适用
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn?s disease - RETIC/03/06
ALFA WASSERMA0 个研究点目标入组 424 人开始时间: 2007年10月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 424
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, 18 to 75 years old, Crohn disease diagnosis localised at ileum or colon and radiologically or spectroscopically documented for at least 3 months, patients with CDAI between 220 and 400, patients capable of and willing to conform to the study protocol, ICF signed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •patients potentially needing immediate surgery for Crohn disease, including patients with occlusive symptoms, patients with other infectious, ischemic, or immunological diseases with gastrointestinal involvement
研究者
相似试验
进行中（未招募）
1 期
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s diseaseEUCTR2007-001014-17-HUAlfa Wassermann S.p.A.424
进行中（未招募）
不适用
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s diseaseTreatment of moderate, active Crohn’s disease: induction of remission.MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-001014-17-DEAlfa Wassermann S.p.A.424
进行中（未招募）
1 期
A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Crohn’s diseaseTreatment of moderate, active Crohn’s disease: induction of remission.MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-001014-17-FRAlfa Wassermann S.p.A.424
进行中（未招募）
不适用
A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad® 50 µg and 100 µg mucoadhesive buccal tablet (MBT) applied once daily in patients to those of placebo in the prevention and treatment of chemoradion therapy-induced oral mucositis in patients with head and neck cancerEUCTR2009-014870-16-FRBioAlliance Pharma183
进行中（未招募）
1 期
Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in the prevention of post-operative endoscopic Crohn’s disease recurrencePost-operative endoscopic Crohn’s disease recurrenceMedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856EUCTR2017-002258-36-DEALFASIGMA S.P.A.180